About this episode

This episode discusses the RASolute 302 trial presented at the 2026 ASCO Plenary, highlighting its significant findings on daraxonrasib's effectiveness in treating mPDAC.

This week’s episode will be focusing on the 2026 ASCO Plenary that received a standing ovation, the RASolute 302 trial. The RASolute 302 trial is a landmark phase 3 study demonstrating that daraxonrasib doubled overall survival compared to chemotherapy in previously treated (2L) metastatic pancreatic ductal adenocarcinoma (mPDAC).

Explore listener stats, chart rankings, contacts and more on the Two Onc Docs podcast page.